Randomised controlled trial of the tolerability and completion of Maraviroc compared to Kaletra; in combination with Truvada; for HIV Post Exposure Prophylaxis.

Trial Profile

Randomised controlled trial of the tolerability and completion of Maraviroc compared to Kaletra; in combination with Truvada; for HIV Post Exposure Prophylaxis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms MiPEP
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Mar 2017 Results published in the Journal of Antimicrobial Chemotherapy
    • 19 Feb 2015 Planned End Date changed from 31 Jan 2015 to 31 Dec 2014 as per United Kingdom Clinical Research Network record.
    • 04 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top